Epoprostenol (Flolan, Veletri)

Epoprostenol (Flolan, Veletri) is covered for FDA‑approved pulmonary arterial hypertension (WHO Group 1) and compendial off‑label use for chronic thromboembolic pulmonary hypertension (CTEPH); use outside these indications is not supported except a one‑time short-term (up to 30‑day) supply while information is obtained. Coverage requires right‑heart catheterization confirmation of PAH, NYHA functional class III–IV (or class II with prior oral or inhaled/parenteral prostacyclin therapy), prescription by or consultation with a pulmonologist or cardiologist, adherence to dosing limits (PAH ≤100 ng/kg/min IV; CTEPH ≤45 ng/kg/min IV), 12‑month approvals, documented clinical benefit for reauthorization, and additional vasodilator/CCB testing or trial documentation for idiopathic PAH.

"Epoprostenol is a prostanoid vasodilator indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise capacity."